277O The ReSPECT-GBM™ phase I/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial is a research paper published in Annals of Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
FWCI
0.54
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals